TherapeuticsMD Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
TherapeuticsMD (TXMD) Misses Q2 EPS by 3c, Revenues Miss
July 30, 2018 6:16 AM EDTTherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.15), $0.03 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.76 million versus the consensus estimate of $4.25 million.
Second Quarter and Recent Developments
Received FDA approval of Imvexxy (estradiol vaginal inserts) on May 29, 2018 for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.Completed the first drawdown of $75 million on June 7, 2018... More